Brokerages Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00

Seres Therapeutics, Inc. (NASDAQ:MCRB) has been assigned an average rating of “Hold” from the five research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $4.00.

Several equities research analysts have issued reports on MCRB shares. Chardan Capital reiterated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research note on Thursday, March 20th. The Goldman Sachs Group dropped their target price on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a report on Friday, March 14th. Finally, StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday.

Seres Therapeutics Stock Up 1.7 %

NASDAQ:MCRB opened at $0.59 on Tuesday. Seres Therapeutics has a twelve month low of $0.46 and a twelve month high of $1.53. The company has a market cap of $102.96 million, a P/E ratio of -2.57 and a beta of 2.54. The business has a 50 day moving average price of $0.72 and a two-hundred day moving average price of $0.79.

Institutional Trading of Seres Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC grew its stake in shares of Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after acquiring an additional 788,762 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 37,866 shares during the last quarter. Northern Trust Corp raised its position in Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 44,461 shares during the last quarter. Geode Capital Management LLC boosted its position in Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock worth $1,256,000 after buying an additional 121,793 shares during the period. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the period. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.